Medivir AB and Tibotec Partner Up To Develop Hepatitis C Polymerase Drug
By focusing in on HCV polymerase NS5B, two companies join forces to develop new and effective medications for inhibiting the Hepatitis C virus.
Medivir AB Broadens Its Hepatitis C Collaboration with Tibotec, Entering a Partnership in the Field of HCV Polymerase
Regulatory News:
Medivir AB (STO:MVIRB) announced today a new Research, Development and License agreement in the field of hepatitis C virus (HCV). Under the agreement, executed with Ortho Biotech Products L.P. of Bridgewater, NJ (a wholly owned subsidiary of Johnson & Johnson), Medivir will partner with Tibotec BVBA of Mechelen, Belgium.
The goal of the HCV partnership is to identify and develop orally active inhibitors of the HCV polymerase NS5B. Activities will centre on screening new and existing libraries of nucleoside analogues, developed by Medivir, that show anti-HCV activity in vitro.
Read the entire article:
http://www.chiroeco.com/chiropractic/news/4114/44/Medivir-AB-Broadens-Its-Hepatitis-C-Collaboration-with-TibotecEntering-a-Partnership-in-the-Field-of-HCV-Polymerase/